Abstract 449P
Background
To evaluate the utility of screening tool in assessment of chemotherapy induced peripheral neuropathy (CIPN) among patients receiving chemotherapy for any cancers by using CIPN screening tool.
Methods
A prospective observational study was conducted in the medical oncology wards of tertiary care hospital in Southern India. The data was extracted from the patient’s evaluation and medical records with known histological malignancies and at least one chemotherapeutic drug prescribed in it. Patients and their caretakers were interviewed after 3rd cycle of chemotherapy and followed up till the end of chemotherapy. Pre-designed and validated questionnaire was administered to the subjects, eviQ screening tool was applied for evaluating (CIPN) symptoms and severity grading was assessed by using CTCAE version 4.3.
Results
A total of 101 cancer patients were recruited into the study based on inclusion and exclusion criteria. 45.5% of patients have developed CIPN. 69.5% of subjects had grade-2 and 30.43% of subjects had developed grade 3 peripheral neuropathy. Gender distribution of subjects had shown that females were more prone to develop CIPN (82.6%). Subjects at the age group of 50-59 years old stood first (23.91%) for CIPN followed by 40-49 years old (21.78%). In Individual therapy paclitaxel (77.7%) showed the higher rate of CIPN followed by cisplatin (26.6%), where as in combination therapy paclitaxel with carboplatin had shown the higher rate of CIPN (53.84%).
Conclusions
Current screening tool is effective for early detection and will give better incidence rate of chemotherapy induced peripheral neuropathy then routine clinical evaluation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract